LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise. LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise.

X

Find the latest Drugs in Development and Pipeline Prospector News of Janssen Pharmaceutical.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Janssen Pharmaceutical
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
1125 Trenton-Harbourton Road, P.O. Box 200, Titusville, NJ 08560
Telephone
Telephone
+1-800-775-5514.
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

TREMFYA (guselkumab) is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor for the treatment of adult patients living with active Psoriatic Arthritis.


Lead Product(s): Guselkumab

Therapeutic Area: Immunology Product Name: Tremfya

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.


Lead Product(s): ADX71149,Levetiracetam

Therapeutic Area: Neurology Product Name: ADX71149

Highest Development Status: Phase IIProduct Type: Small molecule

Recipient: Addex Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TAR-200 monotherapy (gemcitabine intravesical drug delivery system) and cetrelimab monotherapy (intravenous anti-PD-1 mAb) is being evaluated for Bacillus Calmette-Guérin- unresponsive high-risk non-muscle-invasive bladder cancer, who are ineligible for radical cystectomy.


Lead Product(s): Gemcitabine,Cetrelimab

Therapeutic Area: Oncology Product Name: TAR-200

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Akeega is a combination of niraparib, a highly selective poly (ADP ribose) polymerase (PARP) inhibitor and abiraterone acetate, an androgen biosynthesis inhibitor is being studied for adult patients with BRCA1/2 gene mutated metastatic castration resistant prostate cancer.


Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Akeega

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Imbruvica (ibrutinib) is a small-molecule inhibitor of BTK, it was granted NICE approval in combination with venetoclax as first-line treatment option for chronic lymphocytic leukaemia.


Lead Product(s): Ibrutinib,Venetoclax

Therapeutic Area: Oncology Product Name: Imbruvica

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The agreement leverages Pipeline’s expertise in precision neuroregeneration and Janssen’s development experience across nervous system disorders for the investigational compound, PIPE-307, an oral, highly selective antagonist of the muscarinic M1 receptor.


Lead Product(s): PIPE-307

Therapeutic Area: Neurology Product Name: PIPE-307

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: Pipeline Therapeutics

Deal Size: $1,100.0 million Upfront Cash: $50.0 million

Deal Type: Licensing Agreement April 17, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Erleada® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).


Lead Product(s): Apalutamide

Therapeutic Area: Oncology Product Name: Erleada

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Rybrevant® (amivantamab-vmjw) extracellular domains of EGFR and MET which disrupts EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET.


Lead Product(s): Amivantamab-vmjw,Lazertinib,Carboplatin

Therapeutic Area: Oncology Product Name: Rybrevant

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 29, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Spravato® (esketamine) is the S-enantiomer of racemic ketamine, is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.


Lead Product(s): Esketamine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: Spravato

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 27, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Tremfya (guselkumab) is a human monoclonal IgG1 lamda antibody that selectively binds to and inhibits its interaction with IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.


Lead Product(s): Guselkumab

Therapeutic Area: Dermatology Product Name: Tremfya

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY